Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

LQDA

Liquidia Corp

Sep 20 • 04:00PM ET

9.95

Dollar change -0.32
Percentage change -3.12	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF KOMP IWO VTWO XPH VHT IWC ITOT

Index	RUT	P/E	-	EPS (ttm)	-1.57	Insider Own	32.20%	Shs Outstand	68.63M	Perf Week	1.58%
Market Cap	828.34M	Forward P/E	-	EPS next Y	-1.68	Insider Trans	1.09%	Shs Float	56.44M	Perf Month	-0.30%
Income	-112.11M	PEG	-	EPS next Q	-0.39	Inst Own	45.08%	Short Float	21.71%	Perf Quarter	-18.44%
Sales	14.84M	P/S	55.82	EPS this Y	-39.76%	Inst Trans	-3.69%	Short Ratio	9.89	Perf Half Y	-38.73%
Book/sh	0.82	P/B	12.12	EPS next Y	0.57%	ROA	-75.00%	Short Interest	12.26M	Perf Year	58.44%
Cash/sh	1.60	P/C	6.22	EPS next 5Y	-	ROE	-181.73%	52W Range	5.71 - 16.99	Perf YTD	-17.29%
Dividend Est.	-	P/FCF	-	EPS past 5Y	30.44%	ROI	-173.95%	52W High	-41.44%	Beta	0.22
Dividend TTM	-	Quick Ratio	5.78	Sales past 5Y	423.30%	Gross Margin	61.12%	52W Low	74.26%	ATR (14)	0.64
Dividend Ex-Date	-	Current Ratio	6.08	EPS Y/Y TTM	-99.71%	Oper. Margin	-655.83%	RSI (14)	48.15	Volatility	5.84% 5.19%
Employees	136	Debt/Eq	0.05	Sales Y/Y TTM	-16.65%	Profit Margin	-755.46%	Recom	1.25	Target Price	24.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-0.72%	Payout	-	Rel Volume	1.24	Prev Close	10.27
Sales Surprise	-61.28%	EPS Surprise	-8.35%	Sales Q/Q	-23.55%	Earnings	Aug 07 BMO	Avg Volume	1.24M	Price	9.95
SMA20	3.86%	SMA50	-8.37%	SMA200	-19.83%	Trades		Volume	1,531,777	Change	-3.12%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform	$27
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy	$18 → $28
Sep-19-22	Resumed	Wedbush	Underperform	$3
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform	$3
Jul-22-22	Initiated	Ladenburg Thalmann	Buy	$15
May-31-22	Initiated	BTIG Research	Buy	$14
May-26-22	Initiated	BofA Securities	Buy	$12
Dec-04-20	Initiated	H.C. Wainwright	Buy	$6
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral	$20 → $4
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform	$26
Aug-20-18	Initiated	Needham	Buy	$30
Aug-20-18	Initiated	Jefferies	Buy	$22

Show Previous Ratings

Sep-16-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Paragon 28, Centuri, Liquidia, and Elastic and Encourages Investors to Contact the Firm (GlobeNewswire)
09:41AM	Court Finds United Therapeutics' Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million (GlobeNewswire)
Sep-12-24 07:02PM	Caligan Partners LP Bolsters Portfolio with Significant Stake in Liquidia Corp (GuruFocus.com)
07:00AM	Liquidia Technologies (LQDA) Soars 14.1%: Is Further Upside Left in the Stock? (Zacks)
Sep-11-24 08:26AM	Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement (GlobeNewswire) +14.10%
08:00AM	Loading…
Aug-28-24 08:00AM	Liquidia to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-26-24 02:19PM	Jim Cramer Says Liquidia Corporation (LQDA) Has Been Going Down, Down, Down (Insider Monkey)
Aug-22-24 06:00AM	Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD (GlobeNewswire)
Aug-20-24 10:27AM	Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia (Zacks)
06:33AM	Liquidias YUTREPIA inhalation powder gains tentative FDA approval (Pharmaceutical Technology)
Aug-19-24 04:01PM	Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 31% (Investor's Business Daily) -30.62%
11:11AM	Midday movers: B. Riley, HP Inc fall; AMD rises (Investing.com)
06:00AM	U.S. FDA Grants Tentative Approval of YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (GlobeNewswire)
Aug-16-24 06:30AM	Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions (GlobeNewswire)
Aug-09-24 07:45AM	Why Is Liquidia Corporation (LQDA) The Best Among Caligan Partners Top Holdings? (Insider Monkey)
07:40AM	Loading…
Aug-07-24 07:40AM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-24 08:00AM	Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire)
Jun-18-24 08:42AM	Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH) (GlobeNewswire) -6.08%
Jun-03-24 04:33PM	Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics (Investor's Business Daily) +12.67%
07:00AM	District Court Issues Favorable Ruling and Denies United Therapeutics' Request to Block YUTREPIA Launch (GlobeNewswire)
May-29-24 08:00AM	Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-24 03:03AM	Liquidia Corp (LQDA) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ... (GuruFocus.com)
02:05AM	Q1 2024 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-24 09:35AM	Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA) (Zacks)
08:53AM	LQDA Stock Earnings: Liquidia Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-13-24 05:43PM	Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-24 08:00AM	Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD (GlobeNewswire)
May-07-24 08:30AM	Liquidia Corporation to Present at BofA Securities Health Care Conference 2024 (GlobeNewswire)
08:00AM	Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024 (GlobeNewswire)
10:02AM	Loading…
Apr-25-24 10:02AM	Earnings Preview: Liquidia Technologies, Inc. (LQDA) Q1 Earnings Expected to Decline (Zacks)
Apr-02-24 09:00AM	Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 06:00AM	Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA (treprostinil) inhalation powder (GlobeNewswire)
Mar-20-24 01:50AM	Chief Medical Officer Rajeev Saggar Sells Shares of Liquidia Corp (LQDA) (GuruFocus.com)
01:49AM	Insider Sell: CFO and COO Michael Kaseta Sells 12,166 Shares of Liquidia Corp (LQDA) (GuruFocus.com)
Mar-16-24 02:42PM	Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 10:54PM	Q4 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents) +5.36%
07:31AM	Liquidia Corp (LQDA) Reports Full Year 2023 Financial Results (GuruFocus.com)
07:10AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:00AM	Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 06:30AM	Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 (GlobeNewswire)
Feb-21-24 03:17PM	United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings (Benzinga)
06:51AM	UPDATE 3-United Therapeutics starts litigation with FDA over rival Liquidia's drug application (Reuters)
06:24AM	United Therapeutics, in unusual step, sues FDA over rivals drug application (BioPharma Dive)
Jan-30-24 06:30AM	Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress (GlobeNewswire)
Jan-29-24 09:55AM	Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 71.41%: Read This Before Placing a Bet (Zacks)
Jan-25-24 06:25AM	UPDATE 1-US FDA still reviewing Liquidia's inhaled blood pressure drug (Reuters)
06:00AM	Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (treprostinil) inhalation powder (GlobeNewswire)
Jan-19-24 06:30AM	Liquidia Corporation Announces Updates to Operations Leadership (GlobeNewswire)
Jan-09-24 06:21PM	Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 29.94%: Here's is How to Trade (Zacks)
04:56PM	What Makes Liquidia Technologies, Inc. (LQDA) a Strong Momentum Stock: Buy Now? (Zacks)
Jan-08-24 08:22AM	Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims (GlobeNewswire)
Jan-05-24 06:45AM	Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD (GlobeNewswire)
Jan-04-24 09:10AM	Liquidia Corporation Announces $100 Million in New Financings (GlobeNewswire) +7.97%
Jan-02-24 06:45AM	Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 06:45AM	16 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-25-23 08:00AM	Biotech CEOs Are Buying Up Their Surging Stocks (Barrons.com)
Dec-22-23 06:35PM	Peabody Energy, Janus International, and More Stocks See Action From Activist Investors (Barrons.com)
Dec-20-23 04:56PM	U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 ('793 Patent) (GlobeNewswire) +35.70% +5.33%
Dec-19-23 01:02PM	Insider Sell Alert: Chief Medical Officer Rajeev Saggar Sells 14,887 Shares of Liquidia Corp (LQDA) (GuruFocus.com) +5.63%
Dec-12-23 07:13AM	Liquidia Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
Nov-08-23 10:47AM	Liquidia Corporation (NASDAQ:LQDA) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:44AM	Q3 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 07:07AM	Liquidia Corp (LQDA) Reports Q3 2023 Financial Results (GuruFocus.com)
06:30AM	Liquidia Corporation Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 06:30AM	Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023 (GlobeNewswire)
Oct-02-23 07:00AM	Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors (GlobeNewswire)
Sep-25-23 04:09PM	FDA Accepts Submission to Add PH-ILD to YUTREPIA Label (GlobeNewswire)
Sep-06-23 04:30PM	United Therapeutics Corporation Files Lawsuit Alleging Infringement of Tyvaso Patent Already Found to Be Invalid by U.S. Patent Office (GlobeNewswire)
Aug-13-23 05:22AM	Liquidia Corporation (NASDAQ:LQDA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 12:38AM	Q2 2023 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents) -9.13%
Aug-10-23 07:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Liquidia Corporation Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-23 08:17AM	Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023 (GlobeNewswire)
Jul-27-23 09:13AM	Liquidia Stock Down 12% But Insiders Still In US$74k Profit (Simply Wall St.)
06:00AM	Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA (treprostinil) Inhalation Powder (GlobeNewswire)
Jul-25-23 02:37PM	Liquidia stock drops after setback in United Therapeutics dispute (American City Business Journals)
08:25AM	Silver Spring's United Therapeutics claims victory in patent infringement suit against Liquidia (American City Business Journals)
Jul-24-23 01:46PM	U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation (GlobeNewswire) -12.76%
Jun-29-23 11:24AM	Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug (Zacks) -17.68%
Jun-28-23 05:36AM	Liquidia Corporation and Pharmosa Biopharm Announce Collaboration for Sustained-Release Inhaled Treprostinil Product in North America (GlobeNewswire) +10.99%
May-31-23 06:30AM	Liquidia Corporation to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 11:26AM	Investing in Liquidia (NASDAQ:LQDA) a year ago would have delivered you a 106% gain (Simply Wall St.)
May-21-23 03:39PM	Hero or Zero? 7 High-Risk Stocks to Make You Rich Or Broke. (InvestorPlace)
May-19-23 06:15AM	Liquidia Announces Poster Presentation at the 2023 American Thoracic Society International Conference (GlobeNewswire) +6.14%
May-09-23 06:33AM	Institutional investors are Liquidia Corporation's (NASDAQ:LQDA) biggest bettors and were rewarded after last week's US$60m market cap gain (Simply Wall St.)
May-04-23 09:15AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-23 06:45AM	Liquidia Corporation to Present at BofA Securities 2023 Health Care Conference (GlobeNewswire)
Apr-27-23 06:45AM	Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
Apr-20-23 04:17AM	Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength? (Zacks)
Apr-18-23 08:33AM	Liquidia Corporation's (NASDAQ:LQDA) Earnings Haven't Escaped The Attention Of Investors (Simply Wall St.)
Apr-11-23 06:45AM	Liquidia Corporation to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-03-23 06:45AM	Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications (GlobeNewswire)
Mar-25-23 08:33AM	Industry Analysts Just Made A Captivating Upgrade To Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts (Simply Wall St.)
Mar-20-23 04:10AM	Liquidia Corporation (NASDAQ:LQDA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-18-23 08:34AM	Liquidia Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-17-23 03:22AM	Q4 2022 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-16-23 07:55AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +15.25%
06:30AM	Liquidia Corporation Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manning Paul B	Director	Sep 12 '24	Buy	8.90	337,078	2,999,994	816,311	Sep 16 04:05 PM
Caligan Partners LP	Director	Aug 30 '24	Buy	9.51	150,000	1,426,500	6,994,997	Sep 04 05:51 PM
Caligan Partners LP	Director	Aug 30 '24	Sale	9.51	150,000	1,426,500	6,844,997	Sep 04 05:51 PM
Adair Jason	Chief Business Officer	Sep 03 '24	Sale	9.50	455	4,322	115,814	Sep 04 04:51 PM
Schundler Russell	General Counsel	Sep 03 '24	Sale	9.50	710	6,745	488,624	Sep 04 04:44 PM
Moomaw Scott	Chief Commercial Officer	Sep 03 '24	Sale	9.50	546	5,187	154,325	Sep 04 04:44 PM
Kaseta Michael	CFO and COO	Sep 03 '24	Sale	9.50	1,079	10,250	314,968	Sep 04 04:40 PM
Adair Jason	Chief Business Officer	Jul 26 '24	Sale	11.44	1,833	20,970	113,393	Jul 29 04:30 PM
Saggar Rajeev	Chief Medical Officer	Jul 19 '24	Sale	11.13	1,873	20,846	208,329	Jul 22 04:30 PM
JEFFS ROGER	Chief Executive Officer	Jul 12 '24	Sale	12.53	8,053	100,904	818,932	Jul 15 06:32 PM
Moomaw Scott	Chief Commercial Officer	Jul 12 '24	Sale	12.53	1,528	19,146	151,682	Jul 15 06:30 PM
Adair Jason	Chief Business Officer	Jul 12 '24	Sale	12.53	1,146	14,359	115,226	Jul 15 06:28 PM
Schundler Russell	General Counsel	Jul 12 '24	Sale	12.53	1,985	24,872	485,676	Jul 15 06:27 PM
Saggar Rajeev	Chief Medical Officer	Jul 12 '24	Sale	12.53	1,470	18,419	210,202	Jul 15 06:25 PM
Kaseta Michael	CFO and COO	Jul 12 '24	Sale	12.53	3,906	48,942	312,389	Jul 15 06:23 PM
Kaseta Michael	CFO and COO	Jun 03 '24	Sale	14.55	1,094	15,918	316,295	Jun 04 09:26 PM
Adair Jason	Chief Business Officer	Jun 03 '24	Sale	14.55	455	6,620	112,465	Jun 04 09:26 PM
Schundler Russell	General Counsel	Jun 03 '24	Sale	14.55	710	10,330	487,661	Jun 04 09:25 PM
Moomaw Scott	Chief Commercial Officer	Jun 03 '24	Sale	14.55	546	7,944	153,210	Jun 04 09:24 PM
Saggar Rajeev	Chief Medical Officer	Apr 19 '24	Sale	13.68	1,649	22,558	211,672	Apr 23 05:24 PM
Schundler Russell	General Counsel	Apr 12 '24	Sale	14.58	2,060	30,035	486,027	Apr 16 05:17 PM
Saggar Rajeev	Chief Medical Officer	Apr 12 '24	Sale	14.58	1,525	22,234	213,321	Apr 16 05:17 PM
Moomaw Scott	Chief Commercial Officer	Apr 12 '24	Sale	14.58	1,585	23,109	151,881	Apr 16 05:16 PM
Kaseta Michael	CFO and COO	Apr 12 '24	Sale	14.58	3,136	45,723	315,045	Apr 16 05:16 PM
JEFFS ROGER	Chief Executive Officer	Apr 12 '24	Sale	14.58	8,360	121,889	826,985	Apr 16 05:15 PM
Adair Jason	Chief Business Officer	Apr 12 '24	Sale	14.58	1,189	17,336	111,537	Apr 15 08:31 PM
Adair Jason	Chief Business Officer	Mar 18 '24	Sale	15.81	4,657	73,649	108,640	Mar 19 09:50 PM
Schundler Russell	General Counsel	Mar 18 '24	Sale	15.82	8,653	136,890	488,087	Mar 19 09:48 PM
Moomaw Scott	Chief Commercial Officer	Mar 18 '24	Sale	15.82	6,108	96,629	153,466	Mar 19 09:47 PM
Kaseta Michael	CFO and COO	Mar 18 '24	Sale	15.82	12,166	192,466	318,181	Mar 19 09:47 PM
Saggar Rajeev	Chief Medical Officer	Mar 18 '24	Sale	15.82	7,530	119,125	214,846	Mar 19 09:46 PM
JEFFS ROGER	Chief Executive Officer	Mar 18 '24	Sale	15.82	28,583	452,183	835,345	Mar 19 09:46 PM
Moomaw Scott	Chief Commercial Officer	Feb 29 '24	Sale	14.17	546	7,737	159,574	Mar 04 07:07 PM
Adair Jason	Chief Business Officer	Feb 29 '24	Sale	14.17	455	6,447	97,412	Mar 04 07:05 PM
Adair Jason	Chief Business Officer	Dec 18 '23	Sale	7.70	77	593	54,932	Dec 20 05:20 PM
JEFFS ROGER	Chief Executive Officer	Dec 14 '23	Buy	7.16	139,665	1,000,001	640,805	Dec 18 05:02 PM
Manning Paul B	Director	Dec 14 '23	Buy	7.16	279,330	2,000,003	279,330	Dec 18 05:00 PM
Caligan Partners LP	Director	Dec 14 '23	Buy	7.16	1,117,318	7,999,997	11,280,945	Dec 14 04:42 PM
Lippe Robert A	Chief Operations Officer	Nov 30 '23	Sale	7.28	497	3,618	193,788	Dec 05 09:21 PM
Moomaw Scott	Chief Commercial Officer	Nov 30 '23	Sale	7.28	542	3,946	106,737	Dec 05 09:18 PM
Adair Jason	Chief Business Officer	Nov 30 '23	Sale	7.28	452	3,291	54,478	Dec 05 09:15 PM

Dollar change 0.00
Percentage change 0.00	%

ALIM Alimera Sciences Inc. daily Stock Chart

Held by: VXF VTI VTWO VTWG VTWV VTHR

Index	-	P/E	-	EPS (ttm)	-0.31	Insider Own	6.28%	Shs Outstand	52.35M	Perf Week	-0.36%
Market Cap	301.27M	Forward P/E	29.16	EPS next Y	0.19	Insider Trans	0.00%	Shs Float	50.97M	Perf Month	-0.89%
Income	-15.27M	PEG	-	EPS next Q	-0.01	Inst Own	60.32%	Short Float	1.13%	Perf Quarter	73.67%
Sales	99.68M	P/S	3.02	EPS this Y	83.97%	Inst Trans	0.43%	Short Ratio	0.65	Perf Half Y	39.20%
Book/sh	0.74	P/B	7.48	EPS next Y	250.00%	ROA	-9.63%	Short Interest	0.58M	Perf Year	67.88%
Cash/sh	0.20	P/C	27.74	EPS next 5Y	-	ROE	-34.57%	52W Range	2.61 - 5.65	Perf YTD	28.24%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.42%	ROI	-13.83%	52W High	-1.95%	Beta	1.25
Dividend TTM	-	Quick Ratio	2.62	Sales past 5Y	13.40%	Gross Margin	73.97%	52W Low	112.56%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	2.79	EPS Y/Y TTM	90.80%	Oper. Margin	0.85%	RSI (14)	52.49	Volatility	4.98% 1.65%
Employees	159	Debt/Eq	1.86	Sales Y/Y TTM	69.78%	Profit Margin	-15.32%	Recom	3.00	Target Price	6.75
Option/Short	Yes / No	LT Debt/Eq	1.85	EPS Q/Q	95.39%	Payout	-	Rel Volume	0.00	Prev Close	5.54
Sales Surprise	4.89%	EPS Surprise	-63.49%	Sales Q/Q	53.95%	Earnings	Aug 06 BMO	Avg Volume	895.61K	Price	5.54
SMA20	-0.04%	SMA50	-0.33%	SMA200	32.67%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-25-24	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-25-24	Initiated	Maxim Group	Buy	$10
Oct-30-23	Upgrade	Alliance Global Partners	Neutral → Buy	$8
May-28-19	Initiated	Craig Hallum	Buy
Apr-27-17	Initiated	Rodman & Renshaw	Buy	$4
Nov-17-14	Initiated	Summer Street Research	Buy	$12
Sep-29-14	Reiterated	Northland Capital	Outperform	$7 → $10
Oct-28-13	Upgrade	Cowen	Market Perform → Outperform
Oct-08-13	Initiated	Northland Capital	Outperform	$5
Nov-14-11	Downgrade	Rodman & Renshaw	Mkt Outperform → Mkt Perform
Dec-27-10	Reiterated	Oppenheimer	Outperform	$16 → $14
Oct-11-10	Initiated	Rodman & Renshaw	Mkt Outperform	$13
Jun-02-10	Initiated	Oppenheimer	Outperform	$16

Show Previous Ratings

Sep-16-24 08:53AM	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences (GlobeNewswire)
06:50AM	ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences (GlobeNewswire)
Sep-12-24 08:29AM	Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock? (Zacks)
Sep-11-24 06:50AM	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger (GlobeNewswire) +6.55%
Sep-10-24 02:09PM	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences (GlobeNewswire) -6.49%
09:00AM	Loading…
09:00AM	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement (Business Wire)
Aug-09-24 07:43AM	Should You Invest on Alimera Sciences, Inc. (ALIM) Right Now? (Insider Monkey)
Aug-06-24 01:53PM	ALIM Stock Earnings: Alimera Sciences Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
08:40AM	Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:39AM	Alimera Sciences: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Alimera Sciences Reports Second Quarter 2024 Results (GlobeNewswire)
Jun-25-24 11:04AM	Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals (Zacks)
Jun-24-24 11:31AM	Why Is Alimera Sciences (ALIM) Stock Up 77% Today? (InvestorPlace) +75.87%
11:28AM	Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal (Benzinga)
11:14AM	Alimera Sciences shares jump by 77% after being acquired by ANI (Pharmaceutical Technology)
06:50AM	Loading…
06:50AM	ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences (GlobeNewswire)
Jun-04-24 04:30PM	Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-15-24 03:06AM	Alimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ... (GuruFocus.com)
May-14-24 11:53AM	ALIM Stock Earnings: Alimera Sciences Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace) -5.75%
08:40AM	Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:38AM	Alimera Sciences: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Alimera Sciences Reports First Quarter 2024 Results (GlobeNewswire)
May-07-24 08:00AM	Alimera Announces Scientific Data Highlighting YUTIQ to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences (GlobeNewswire)
Apr-30-24 08:00AM	Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update (GlobeNewswire)
Mar-20-24 08:00AM	Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-19-24 08:00AM	Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network (GlobeNewswire)
Mar-08-24 10:05AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 11:18PM	Q4 2023 Alimera Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
01:55PM	Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
12:52PM	ALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023 (InvestorPlace)
09:00AM	Loading…
09:00AM	Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:11AM	Alimera Sciences: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Feb-29-24 08:00AM	Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update (GlobeNewswire) +5.99%
Feb-08-24 08:00AM	The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN (GlobeNewswire)
Jan-04-24 08:00AM	Alimera Completes Recruitment for the Synchronicity Study (GlobeNewswire)
Jan-02-24 08:00AM	Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.56%
Dec-12-23 07:30AM	Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-08-23 04:30PM	Alimera Appoints Maggie A. Pax to Its Board of Directors (GlobeNewswire)
Oct-31-23 08:00AM	Alimera Announces Scientific Data Highlighting ILUVIEN To Be Presented at the American Academy of Ophthalmology (GlobeNewswire)
Oct-27-23 09:26AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-26-23 09:29AM	Alimera Sciences Inc (ALIM) Reports Q3 2023 Financial Results (GuruFocus.com)
08:30AM	Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:18AM	Alimera Sciences: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Alimera Sciences Reports Third Quarter 2023 Results (GlobeNewswire)
Oct-16-23 08:00AM	Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update (GlobeNewswire) +14.83%
Oct-11-23 08:00AM	Alimera Announces Multiple Presentations Highlighting ILUVIEN and YUTIQ Data at Retina Society Annual Congress (GlobeNewswire) -5.75%
Oct-03-23 08:00AM	Alimera Sciences Appoints Jason Werner as Chief Operating Officer (GlobeNewswire)
Sep-16-23 03:01AM	Caligan Partners LP Reduces Stake in Alimera Sciences Inc (GuruFocus.com)
Sep-05-23 08:00AM	Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -7.04%
Aug-23-23 09:02AM	Altium Capital Management LP Acquires New Stake in Alimera Sciences Inc (GuruFocus.com)
Aug-13-23 04:37AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:21AM	Stonepine Capital Management, LLC Acquires New Stake in Alimera Sciences Inc (GuruFocus.com)
Aug-10-23 10:00PM	Q2 2023 Alimera Sciences Inc Earnings Call (Thomson Reuters StreetEvents) +7.03%
08:50AM	Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:47AM	Alimera Sciences: Q2 Earnings Snapshot (AP Finance)
07:30AM	Alimera Sciences Reports Second Quarter 2023 Results (GlobeNewswire)
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
Aug-03-23 07:03PM	Velan Capital Investment Management LP Boosts Stake in Alimera Sciences Inc (GuruFocus.com) +6.45%
Aug-02-23 11:43AM	Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update (GlobeNewswire) -5.20%
Jul-07-23 09:40AM	Are Medical Stocks Lagging 89BIO (ETNB) This Year? (Zacks)
Jun-08-23 08:50AM	Alimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced Momentum (Zacks) -5.15%
Jun-01-23 09:40AM	Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year? (Zacks) -5.09%
May-25-23 10:15AM	Alimera (ALIM) Completes Enrollment in Eye Disease Study (Zacks)
May-24-23 08:00AM	Alimera Completes Recruitment for its Landmark NEW DAY Study (GlobeNewswire) +8.09%
May-23-23 08:50AM	Alimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks) -7.84%
May-19-23 12:01PM	Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq (Zacks) -6.50%
May-18-23 10:29PM	Q1 2023 Alimera Sciences Inc Earnings Call (Thomson Reuters StreetEvents) +19.42%
09:02AM	EyePoint Pharma Offloads Its Commercially-Available Eye Implant For $82.5M Plus Royalties (Benzinga)
07:00AM	Alimera Acquires U.S. Commercial Rights to YUTIQ® (GlobeNewswire)
May-17-23 04:05PM	Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET (GlobeNewswire) +9.57%
May-15-23 09:05AM	Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:50AM	Alimera Sciences Reports First Quarter 2023 Results (GlobeNewswire)
May-08-23 08:00AM	Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update (GlobeNewswire) -5.26%
May-01-23 10:01AM	Will Alimera Sciences (ALIM) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-20-23 08:00AM	Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress (GlobeNewswire)
Apr-17-23 07:20AM	There's No Escaping Alimera Sciences, Inc.'s (NASDAQ:ALIM) Muted Revenues Despite A 27% Share Price Rise (Simply Wall St.)
Apr-04-23 01:18PM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-03-23 08:09AM	When Will Alimera Sciences, Inc. (NASDAQ:ALIM) Breakeven? (Simply Wall St.) -5.24%
08:00AM	Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries (GlobeNewswire)
Mar-31-23 09:15AM	Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +17.98%
08:00AM	Alimera Sciences Announces 2022 Financial Results and Business Update (GlobeNewswire)
Mar-27-23 08:00AM	Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility (GlobeNewswire) +36.91%
Mar-24-23 04:05PM	Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update (GlobeNewswire)
Feb-27-23 08:00AM	Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors (GlobeNewswire)
Feb-22-23 08:00AM	Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN® (GlobeNewswire) -5.44%
Jan-09-23 08:00AM	Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer (GlobeNewswire)
Dec-29-22 06:02AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call Transcript (Insider Monkey) +10.76%
Dec-08-22 08:00AM	Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement (GlobeNewswire)
Nov-29-22 08:00AM	Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration (GlobeNewswire)
Nov-17-22 03:54PM	7 Stocks That Could Implode at Any Moment (InvestorPlace)
Nov-16-22 05:05AM	Alimera Sciences Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -9.38%
Nov-14-22 08:55AM	Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Alimera Sciences Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 08:00AM	Alimera Sciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022, and Provide Corporate Update (GlobeNewswire)
Nov-01-22 08:00AM	Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic (GlobeNewswire)
Oct-20-22 09:40AM	Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-18-22 09:03AM	10 Best Low Price Pharma Stocks To Buy Now (Insider Monkey) +6.11%
Oct-06-22 08:00AM	Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments (GlobeNewswire) +6.81%
Sep-23-22 08:00AM	Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network (GlobeNewswire)

Alimera Sciences is a pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. The company is passionate about protecting the retina and developing innovative treatments to preserve vision.

LQDA

Liquidia Corp

ALIM

Alimera Sciences Inc.

Upgrade your FINVIZ experience